Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS

    Nephrology Dialysis Transplantation Date published:

  • TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6

    Nephrology Dialysis Transplantation Date published:

  • Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

    Diabetes Care Date published:

  • Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

    Journal of the American Society of Nephrology Date published:

  • 1054-05 EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Date published:

  • EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

    Date published:

  • SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS

    Kidney International Reports Date published:

  • SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA - A SYSTEMATIC REVIEW AND ANALYSIS

    Kidney International Reports Date published:

  • SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES

    Kidney International Reports Date published:

  • CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

    Journal of the American College of Cardiology Date published:

  • THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Journal of the American Heart Association Date published:

  • Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%

    Circulation Date published:

  • Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

    JACC: Heart Failure Date published:

  • Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

    Diabetes, Obesity and Metabolism Date published: